MX2021013729A - Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo. - Google Patents

Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo.

Info

Publication number
MX2021013729A
MX2021013729A MX2021013729A MX2021013729A MX2021013729A MX 2021013729 A MX2021013729 A MX 2021013729A MX 2021013729 A MX2021013729 A MX 2021013729A MX 2021013729 A MX2021013729 A MX 2021013729A MX 2021013729 A MX2021013729 A MX 2021013729A
Authority
MX
Mexico
Prior art keywords
crystallization
preparation
iap inhibitor
smac mimic
mimic used
Prior art date
Application number
MX2021013729A
Other languages
English (en)
Inventor
Zhaobing Xu
Shuhui Chen
Lihong Hu
Yingchun Liu
DING Charles Z
Xingxun Zhu
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of MX2021013729A publication Critical patent/MX2021013729A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan una cristalina de un imitador de SMAC utilizado como inhibidor de IAP y un método de preparación del mismo; también comprende el uso de dicha cristalina en la preparación de un medicamento para tratar el cáncer que se beneficia de la inhibición de cIAP1; la cristalina del compuesto de fórmula (I) tiene alta estabilidad y baja higroscopicidad, y tiene ventajas en términos de propiedades físicas, seguridad y estabilidad metabólica, y tiene un alto valor como medicamento. (ver Fórmula).
MX2021013729A 2019-05-10 2020-05-09 Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo. MX2021013729A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910389970 2019-05-10
PCT/CN2020/089437 WO2020228642A1 (zh) 2019-05-10 2020-05-09 一种用作iap抑制剂的smac模拟物的结晶及其制备方法

Publications (1)

Publication Number Publication Date
MX2021013729A true MX2021013729A (es) 2021-12-10

Family

ID=73290153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013729A MX2021013729A (es) 2019-05-10 2020-05-09 Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo.

Country Status (13)

Country Link
US (1) US20220177453A1 (es)
EP (1) EP3967702B1 (es)
JP (1) JP2022531794A (es)
KR (1) KR20220006611A (es)
CN (1) CN113748119B (es)
AU (1) AU2020274768A1 (es)
BR (1) BR112021022509A2 (es)
CA (1) CA3138411A1 (es)
DK (1) DK3967702T3 (es)
FI (1) FI3967702T3 (es)
MX (1) MX2021013729A (es)
PT (1) PT3967702T (es)
WO (1) WO2020228642A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101035802A (zh) * 2004-07-02 2007-09-12 健泰科生物技术公司 Iap抑制剂
KR20120127754A (ko) * 2004-12-20 2012-11-23 제넨테크, 인크. Ｉａｐ의 피롤리딘 억제제
JP5452223B2 (ja) * 2006-07-24 2014-03-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
CA2666112A1 (en) * 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
CN101605786A (zh) * 2006-12-19 2009-12-16 健泰科生物技术公司 细胞凋亡抑制剂的咪唑并吡啶抑制剂
AU2009206588A1 (en) * 2008-01-24 2009-07-30 Tetralogic Pharmaceuticals Corporation IAP inhibitors
WO2019091492A1 (zh) * 2017-11-13 2019-05-16 南京明德新药研发股份有限公司 用作iap抑制剂的smac模拟物及其用途

Also Published As

Publication number Publication date
WO2020228642A9 (zh) 2021-10-21
DK3967702T3 (da) 2024-04-15
WO2020228642A1 (zh) 2020-11-19
EP3967702A1 (en) 2022-03-16
JP2022531794A (ja) 2022-07-11
EP3967702A4 (en) 2023-01-11
PT3967702T (pt) 2024-04-09
EP3967702B1 (en) 2024-03-20
US20220177453A1 (en) 2022-06-09
FI3967702T3 (fi) 2024-04-16
CA3138411A1 (en) 2020-11-19
CN113748119A (zh) 2021-12-03
BR112021022509A2 (pt) 2021-12-28
KR20220006611A (ko) 2022-01-17
CN113748119B (zh) 2024-04-02
AU2020274768A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CR20210083A (es) Compuestos de anillo fusionado
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
MX2020012520A (es) Macrociclos con grupos p2' heterociclicos como inhibidores del factor xia.
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
MX2019012945A (es) Formas cristalinas de un compuesto inhibidor de jak.
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2018201167A3 (en) Propionic acid derivatives and methods of use thereof
PH12021550713A1 (en) Medicament for the treatment of chronic cough
WO2018035346A8 (en) KINASE INHIBITING COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CANCER
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
CR20210495A (es) Compuestos macrocíclicos como agonistas de sting
MX2022000939A (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos.
PH12020552152A1 (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
MX2021008712A (es) Derivados heterociclicos.
NZ751777A (en) Pharmaceutical composition and methods of uses
MX2021013729A (es) Cristalina de imitador smac utilizado como inhibidor de iap y metodo de preparacion del mismo.
CR20210181A (es) Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
BR112023023578A2 (pt) Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda
BR112023005443A2 (pt) Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo